GSK's China sales 'a little better' says Dingemans
This article was originally published in Scrip
GlaxoSmithKline saw sales in China getting "a little bit better" at the end of the third quarter of 2013, according to finance chief Simon Dingemans who was speaking at the JP Morgan healthcare meeting earlier this week. GSK reported a 61% drop in revenues during the third quarter following an ongoing bribery investigation, something AstraZeneca CEO Pascal Soriot couldn't help commenting on when he spoke at JPM (scripintelligence.com, 15 January 2014).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.